Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Figure 1

Trial design. *Dose escalation to 50 mg once daily and/or reduction to 40, 30, then 20 mg once daily. †Dose can be escalated to 50 mg/m2 weekly and/or reduction to 40, 30, then 20 mg/m2 weekly. HNSCC = head and neck squamous cell carcinoma; CT = chemotherapy; MTX = methotrexate; PFS = progression-free survival.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us